Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do white matter hyperintensities account for the relationship between discrimination and memory?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.

JAMA neurology·2026
Same author

Closing the Gate Before the Horse is out of the Barn: A Model to Effectively Predict the First Fall in Patients with Parkinson's Disease.

Movement disorders clinical practice·2026
Same author

Social Relations Across Race/Ethnic Groups and Links to Cognitive Health.

Journal of aging and health·2026
Same author

Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center.

Parkinsonism & related disorders·2026
Same author

Data-driven neurobiological subtyping of Parkinson's disease using diffusion MRI-derived isotropic diffusion.

Neuroradiology·2026
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

Parkinson's psychosis.

Laura B Zahodne1, Hubert H Fernandez

  • 1Department of Clinical & Health Psychology, University of Florida, P.O. Box 100165, Gainesville, FL, 32610-0165, USA.

Current Treatment Options in Neurology
|September 16, 2010
PubMed
Summary
This summary is machine-generated.

Psychosis in Parkinson's disease (PD) significantly impacts patients and caregivers. Effective management involves addressing underlying causes, optimizing anti-PD medications, and considering atypical antipsychotics like clozapine or quetiapine.

More Related Videos

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

Related Experiment Videos

Last Updated: Jun 8, 2026

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

Area of Science:

  • Neurology
  • Psychiatry

Background:

  • Psychosis is a common and serious complication in Parkinson's disease (PD).
  • It is a major cause of nursing home placement and increased mortality risk in PD patients.
  • Psychosis in PD presents a significant burden for caregivers.

Purpose of the Study:

  • To review current treatment strategies for psychosis in Parkinson's disease.
  • To emphasize the importance of recognizing and managing PD psychosis.

Main Methods:

  • Literature review of established and emerging treatment options for PD psychosis.
  • Discussion of pharmacologic and non-pharmacologic interventions.

Main Results:

  • Treatment should first address potential medical and environmental causes of delirium.
  • Optimizing anti-Parkinson's disease (anti-PD) medications by reducing adjunctive agents is a crucial initial step.
  • Atypical antipsychotics, particularly clozapine and quetiapine, are recommended when initial measures fail.

Conclusions:

  • Appropriate management of psychosis in PD is essential for patient well-being and caregiver support.
  • Emerging therapies including acetylcholinesterase inhibitors, antidepressants, and cognitive behavioral therapy show promise.
  • A systematic approach, starting with addressing delirium and optimizing PD medications, is key before introducing antipsychotics.